The global urinary tract infection (UTI) treatment market was valued at US$ xx Bn in 2016, and is expected to reach US$ xx Bn by 2025, expanding at a CAGR of 3.2% from 2017 to 2025.
Browse the full report Urinary Tract Infection (UTI) Treatment Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at https://www.credenceresearch.com/report/urinary-tract-infection-uti-treatment-market
Market Insights:
Urinary tract infection (UTI) is a common infections of the urinary tract, which consists of the kidneys, ureters, bladder, urethra or prostate gland. For the purpose of the study UTI treatment market is segmented on the basis of drug type such as penicillin, quinolones, cephalosporin, sulphonamides, tetracycline and other. Among the considered drug type, demand for quinolones is highest in market as these are preferred as first line treatment option. Physician generally prescribe a quinolone medicine if there is no other treatment options existing for a treatment of complicated UTI or kidney infection. In the base year 2016, North America dominated the global UTI treatment market due to large number of target population, higher treatment awareness, swift adoption of novel medications, better reimbursement policies acting as the prime contributors to the dominance of North America. On the other hand, Asia Pacific will show highest UTI treatment market growth during forecast period due to increasing healthcare awareness among general population and growing partnership of key players with local manufacturer.
Market Competition Assessment:
The urinary tract infection (UTI) treatment market is observed to be highly competitive and comprises large number of players. However, some major market players are AstraZeneca plc., Bayer AG, Cubist Pharmaceuticals, F. Hoffmann–La Roche Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Johnson & Johnson, MerLion Pharmaceuticals, Osel Inc., Pfizer Inc., Rempex Pharmaceuticals and other.
Key Market Movements:
- Factors such as increase in prevalence of UTI, higher treatment compliance, changing lifestyle pattern and favorable reimbursement policies in some countries are driving the growth of UTI treatment market worldwide.
- Rising access for the treatment medication in developing countries would fuel the growth of UTI treatment market during forecast period.
- However, generic erosion, poor patient compliance in some countries and adverse effects associated with the use of medication is negatively impacting the growth of UTI treatment market.
Get Sample Copy / request For Customization: https://www.credenceresearch.com/sample-request/58749
ToC:
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Urinary Tract Infection (UTI) Treatment Market Snapshot
2.2 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
2.3 Global Urinary Tract Infection (UTI) Treatment Market Share, by Geography, 2016 (Value %)
Chapter 3 Urinary Tract Infection (UTI) Treatment Market Analysis
3.1 Global Urinary Tract Infection (UTI) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Urinary Tract Infection (UTI) Treatment Market
3.5 Top 3 Countries
Chapter 4 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
4.1 Overview
4.2 Attractive Investment Proposition: Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
4.3 Penicillin
4.4 Quinolones
4.5 Cephalosporin
4.6 Sulphonamides
4.7 Tetracycline
4.8 Other
Chapter 5 Global Urinary Tract Infection (UTI) Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.2.2 North America Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.3.2 Europe Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.4.1 Asia Pacific Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.5.2 Latin America Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.6.2 Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
Chapter 6 Company Profiles
6.1 AstraZeneca plc.
6.2 Bayer AG
6.3 Cubist Pharmaceuticals
6.4 F. Hoffmann–La Roche Ltd.
6.5 GlaxoSmithKline Pharmaceuticals Ltd.
6.6 Johnson & Johnson
6.7 MerLion Pharmaceuticals
6.8 Osel Inc.
6.9 Pfizer Inc.
6.10 Rempex Pharmaceuticals
Get Sample Copy / request For Customization: https://www.credenceresearch.com/sample-request/58749
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations,
governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance
with making enduring enhancements to their execution and understand their most imperative objectives.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-800-361-8290
E-mail: sales@credenceresearch.com